Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?

Table 1 Efficacy of the MMX mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC

Study	Phase	Patient number (n)	Dosing regimen (g/d)	Duration	Remission rates (%)
					Treatment	Placebo
Induction
D’Haens[14]	II	38	MMX 1.2		0
			MMX 2.4	8 wk	30.8	-
			MMX 4.8		18
Lichtenstein[15]	III	280	MMX 2.4	8 wk	34.1a	12.9
			MMX 4.8		29.2a
Kamm[16]	III	343	MMX 2.4	8 wk	40.5a
			MMX 4.8		41.2a	22.1
			Asacol™ 2.4		32.6
Sandborn[17], combined[2526]	III		MMX 2.4	8 wk	37.2a	17.5
			MMX 4.8		35.1a
Maintenance					Patients still in remission
Kamm[21]	III	459	MMX 2.4 od	12 mo	67.8
			MMX 2.4 bid		72.3
Prantera[26]	III	325	MMX 2.4 od	12 mo	69.2b
			Asacol™ 2.4 bid		56.8

^aP < 0.01 vs placebo;

^bP < 0.05, od vs bid remission rates: endoscopic and clinical remission rates.